Heterogeneous treatment effects in Ankylosing spondylitis: an IPD meta-analysis

Ankylosing spondylitis (AS) is a long-term condition that mainly affects the spine, causing pain and stiffness. It can significantly impact a person’s quality of life, as movement becomes difficult due to inflammation in the spine and other joints. Inflammation is when the body's immune system mistakenly attacks its own tissues, causing swelling, pain, and redness. In ankylosing spondylitis, this inflammation typically affects the joints in the spine and can lead to further damage and difficulty moving over time.

This condition affects approximately 0.1% to 0.5% of the population. Current treatment options include tumor necrosis factor inhibitors (TNFi). TNFi are a class of medications used to treat ankylosing spondylitis by targeting and blocking the effects of TNF, a protein that causes inflammation. By reducing TNF activity, these inhibitors help to alleviate pain, stiffness, and other symptoms associated with AS. However, not all patients respond in the same way to these treatments, which can lead to unnecessary side effects and delays in finding a more effective therapy.

This research aims to focus on one class of TNFi called monoclonal antibodies (anti-TNF mAbs). By identifying which patients are most likely to benefit from anti-TNF mAbs, the right treatment can be provided to the right person, benefiting the decision-making of drug choice. Using large datasets from previous studies, the research team will estimate differences in how individual patients respond to mAbs. The goal is to develop a tool that groups patients based on shared characteristics and predicts how they will respond to certain therapies. This tool will use advanced data analysis methods, including machine learning, to identify patterns in drug response.

The insights gained from this research may help doctors make more personalized treatment decisions, improving patient outcomes and reducing unnecessary treatments. In the future, this research could also guide further studies on how patients’ unique biological characteristics, such as how drugs are absorbed and processed in their bodies or the role of inflammatory proteins, influence their response to therapy.